Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

12 trials with published results (8%)

Research Maturity

72 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.5%

7 terminated out of 157 trials

Success Rate

91.1%

+4.6% vs benchmark

Late-Stage Pipeline

8%

12 trials in Phase 3/4

Results Transparency

17%

12 of 72 completed with results

Key Signals

12 with results91% success

Data Visualizations

Phase Distribution

75Total
Not Applicable (30)
Early P 1 (1)
P 1 (8)
P 2 (24)
P 3 (6)
P 4 (6)

Trial Status

Completed72
Unknown33
Recruiting26
Active Not Recruiting10
Terminated7
Withdrawn5

Trial Success Rate

91.1%

Benchmark: 86.6%

Based on 72 completed trials

Clinical Trials (157)

Showing 20 of 20 trials
NCT06610019Recruiting

Cardiovascular Multimodality Imaging Study

NCT06347159Phase 2Active Not RecruitingPrimary

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NCT02432092Recruiting

Pediatric Cardiomyopathy Mutation Analysis

NCT04712136Not ApplicableCompleted

Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations

NCT07361289RecruitingPrimary

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

NCT06549608CompletedPrimary

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

NCT04129905Not ApplicableCompletedPrimary

Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies

NCT02590809Phase 2CompletedPrimary

Hypertrophic Cardiomyopathy Symptom Release by BX1514M

NCT06290570Active Not RecruitingPrimary

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT05836259Phase 1RecruitingPrimary

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05182658Phase 3Active Not RecruitingPrimary

Empagliflozin in Hypertrophic Cardiomyopathy

NCT03723655Phase 2CompletedPrimary

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

NCT05938283Not ApplicableCompleted

Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

NCT06775886Not ApplicableTerminated

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT04112290Active Not RecruitingPrimary

A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT06269640Not ApplicableTerminatedPrimary

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

NCT06368518RecruitingPrimary

Austrian Hypertrophic Cardiomyopathy Registry

NCT05818605Not ApplicableRecruitingPrimary

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

NCT07033455Early Phase 1CompletedPrimary

A Trial of HRS-1893 in Healthy Volunteers

Scroll to load more

Research Network

Activity Timeline